| 摘要 |
The present invention provides a method for treating a condition associated with muscarinic receptor modulation using a 3-Ä4-(butylthio)-1,2,5-thiadiazol-3-ylÜ-1-azabicyclo-Ä2.2.2Üoctane transdermal formulation. The invention provides desired transdermal 3-Ä4-(butylthio)-1,2,5-thiadiazol-3-ylÜ-1-azabicycloÄ2.2.2Üoctane patch formulations. |
